The Oncology Network is delighted to share the second part of a new episode of The Oncology Journal Club podcast with you. The team continue their review of the biggest practice-changers in 2023.
With a trans-Tasman lens, our new Host team includes Professor Craig Underhill, Dr. Kate Clarke and Professor Christopher Jackson.
If you haven’t listened to Part 1 yet we suggest you start there as you don’t want to miss Main Papers and the interview with Kate Burbury.
Today’s guests are Professor Chris Booth and Associate Professor Kate Burbury.
We hope you enjoy the return of the OJC.
PAPERS:
Alexander M, et al. Risk-Directed Ambulatory Thromboprophylaxis in Lung and Gastrointestinal Cancers: The TARGET-TP Randomized Clinical Trial. JAMA Oncol. 2023;9(11):1536–1545. doi:10.1001/jamaoncol.2023.3634. Access online here.
Modi S, et al. Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer. N Engl J Med 2022; 387:9-20. July 7, 2022. Access online here.
Key NS, et al. Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Guideline Update. J Clin Oncol. 2023 Jun 1;41(16):3063-3071. doi: 10.1200/JCO.23.00294. Epub 2023 Apr 19. PMID: 37075273. Access online here.
QUICK BITES
Partridge, AH, et al. Interrupting Endocrine Therapy to Attempt Pregnancy after Breast Cancer. N Engl J Med 2023; 388:1645-1656
DOI: 10.1056/NEJMoa2212856. Access online here.
Lambertini M, et al. Pregnancy after breast cancer in young women with germline BRCA pathogenic variants: Results from an international cohort study. Presented at SABCS 2023. December 5-9, 2023. San Antonio, TX. Abstract GS02-13. Access online here.
Sonke, GS, et al. Primary outcome analysis of the phase 3 SONIA trial (BOOG 2017-03) on selecting the optimal position of cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors for patients with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC). Journal of Clinical Oncology 2023 41:17_suppl, LBA1000. Access online here.
Arnold, C., Webster, P. 11 clinical trials that will shape medicine in 2024. Nat Med 29, 2964–2968 (2023). Access online here.
EV-302/KEYNOTE-A39: Open-label, randomized phase III study of enfortumab vedotin in combination with pembrolizumab vs chemotherapy in previously untreated locally advanced metastatic urothelial carcinoma Access online here.
Sandhya L, et al. Randomized Double-Blind Placebo-Controlled Study of Olanzapine for Chemotherapy-Related Anorexia in Patients With Locally Advanced or Metastatic Gastric, Hepatopancreaticobiliary, and Lung Cancer. J Clin Oncol. 2023 May 10;41(14):2617-2627. doi: 10.1200/JCO.22.01997. Epub 2023 Mar 28. PMID: 36977285. Access online here.
Dijkstra EA, et al. Locoregional Failure During and After Short-course Radiotherapy Followed by Chemotherapy and Surgery Compared With Long-course Chemoradiotherapy and Surgery: A 5-Year Follow-up of the RAPIDO Trial. Ann Surg. 2023 Oct 1;278(4):e766-e772. doi: 10.1097/SLA.0000000000005799. Epub 2023 Jan 20. PMID: 36661037; PMCID: PMC10481913. Access online here.
Basch E, et al. Patient-Reported Outcomes During and After Treatment for Locally Advanced Rectal Cancer in the PROSPECT Trial (Alliance N1048). J Clin Oncol. 2023 Jul 20;41(21):3724-3734. doi: 10.1200/JCO.23.00903. Epub 2023 Jun 4. PMID: 37270691; PMCID: PMC10351948. Access online here.
Patel SP, et al. Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma. N Engl J Med. 2023 Mar 2;388(9):813-823. doi: 10.1056/NEJMoa2211437. PMID: 36856617; PMCID: PMC10410527. Access online here.
RESOURCES
HOSTS:
Craig Underhill
Professor Craig Underhill
Professor Craig Underhill completed his Bachelor of Medicine and Surgery in 1987 at Melbourne University. He completed medical oncology training in Melbourne and worked as the Senior Clinical Research Registrar at Guy’s Hospital, London.
In 1998 arrived in Albury-Wodonga and established a medical oncology practice and clinical trials unit which has developed expertise and infrastructure to ensure the initiation of high quality trials. The research Unit lead by Dr Underhill has twice been awarded NSW Premier’s Award for Innovation in Cancer Clinical Trials, the inaugural award in 2009 and then again in 2012.
Dr Underhill is the VCCC Regional Oncology Lead and advocates for the increased access to clinical trials for regional Victorians and leads the VCCC teletrials program.
You can find Craig on X/Twitter here: @CraigUnderhill
Kate Clarke
Dr. Kate Clarke
Dr Kate Clarke (MBChB (Otago), FRACP) is a proud New Zealander with a real love for beautiful Aotearoa. Dr Clarke continues to work at being Tangata Tiriti. Much of her research and patient advocacy has an equity focus. Dr Clarke is grateful to her patients, students, whanau and colleagues for the knowledge and awhi they share. Ehara taku toa, he takitahi, he toa takitini.
Dr Clarke completed her medical training in Otago, Wellington and London. She has a holistic approach and is passionate about patient-centred care, and believes patients can and should play an active role in their healthcare. Her clinical experience covers a broad range of solid tumour malignancies with special clinical interest in colorectal cancer, upper gastrointestinal cancers and breast cancer.
Chris ‘CJ’ Jackson
Professor Christopher Jackson
Chris Jackson is Professor of Medical Oncology at the University of Otago, Dunedin, and a medical oncologist at Dunedin Hospital and Mercy Cancer Care. He specialises in GI cancers and melanoma, teaches medical students and specialists-in-training, and is heavily involved in both national and international cancer policy, leadership and research.
He was previously the medical director of the Cancer Society of NZ, and his advocacy led to the funding of new cancer drugs, to the development of a new national cancer plan, and to the birth of the national cancer agency Te Aho o Te Kahu. He currently chairs the agency’s clinical committee and serves on the advisory board. In addition, he is on the programme board of the International Cancer Benchmarking Project, and is a founding member of the Common Sense Oncology movement.
Chris is a self-confessed Radiohead tragic, and recent convert to Crossfit (even though you didn’t ask).
Connect with CJ on X/Twitter: @drkiwicj
GUESTS:
Kate Burbury
Associate Professor Kate Burbury
Associate Professor Kate Burbury is a consultant haematologist, clinician-researcher and Executive Director of Digital and Healthcare Innovations at Peter MacCallum Cancer Centre. Prior to moving to executive role, she was lead clinician for MPN/CML, as well as the haemostasis/thrombosis and peri-procedural optimisation, including prehabilitation; Chair of Senior Medical Staff and Deputy Chief Medical Officer at PeterMac.
Associate Professor Burbury is a leading digital health expert which has translated to strategy development, collaborative capacity building, workforce development and a data/digital vehicle pipeline. Her clinical and research program generates multidisciplinary and multimodality collaborations to ensure strategy and focus are directed to key priority health areas, “gaps” in cancer care delivery and translation of scientific discovery and developments into the clinic.
Chris Booth
Professor Christopher Booth
Christopher Booth MD FRCPC is a Medical Oncologist and Health Services Researcher at Queen’s University in Kingston, Ontario, Canada. He is a Professor of Oncology and Public Health Sciences and holds the Canada Research Chair in Population Cancer Care. Dr. Booth is the Director of the Division of Cancer Care and Epidemiology at Queen’s Cancer Research Institute (QCRI). Dr. Booth studied medicine at Queen’s University. He did postgraduate training in Internal Medicine and Medical Oncology at the University of Toronto followed by a research fellowship with the NCIC Clinical Trials Group. In his clinical practice he provides care to patients with gastrointestinal cancers. Dr. Booth’s research program explores access, quality, and value of cancer care in Canada and globally.
PRODUCER:
Rachael Babin
Rachael Babin is Host of The Oncology Podcast, Editor-in-Chief of The Oncology Newsletter, and Publisher of Oncology News Australia and The Oncology Network.
With a background in oncology communications and academic publishing, Rachael is happiest sitting behind the mic chatting to interesting people about the impact their work makes in oncology.
Connect on Twitter: @OncologyNewsAus
